HC Wainwright & Co. Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price Target of $16

Benzinga Newsdesk www.benzinga.com Neutral 64.3%

Neg 0% Neu 64.3% Pos 0%

HC Wainwright & Co. analyst Robert Burns initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and announces Price Target of $16.